Fundraising Fox

bright-minds

New York, US · Founded 2019 · 1 known investors

brightmindsbio.com ↗

Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.

BiotechDeep TechHealthtech

Founders & leadership

bright-minds was founded in 2019 by Alan Kozikowski and Ian McDonald.

AK
Alan KozikowskiCo-founder
IM
Ian McDonald
RC
Ryan CheungChief Financial Officer
JP
JAN PEDERSENChief Science Officer
GS
Gideon ShapiroExecutive
RS
Revati SheeniwasExecutive

Board

DW
DAVID WEINERBoard director
NC
NILS CHRISTIAN BOTTLERBoard director
JF
JEREMY FRYZUKBoard director

Investors · 1

PsyMed VenturesBerkeley

Reported raises · per SEC filings

Form D private placements

$36.6M disclosed across 9 of 14 rounds · 2020–2024

▶$34.6MraisedNov 2024 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M WeinerDirector
  • Jan Torleif PedersenExecutive Officer, Director
  • Jeremy FryzukDirector
  • Nils BottlerDirector
  • Ian McDonaldExecutive Officer, Director
  • Ryan CheungExecutive Officer
Offering amount
$34.6M
Amount sold
$34.6M
First sale
Nov 2024
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.2KofferedOct 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • IAN McDONALDExecutive Officer, Director
  • RYAN CHEUNGExecutive Officer
  • DAVID WEINERDirector
  • NILS CHRISTIAN BOTTLERDirector
  • JEREMY FRYZUKDirector
  • JAN PEDERSENExecutive Officer, Director
Offering amount
$12.2K
First sale
Oct 2024
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$54.2KofferedMay 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • IAN McDONALDExecutive Officer, Director
  • RYAN CHEUNGExecutive Officer
  • DAVID WEINERDirector
  • JEREMY FRYZUKDirector
  • NILS CHRISTIAN BOTTLERDirector
  • MARK SMITHExecutive Officer
  • JAN PEDERSENExecutive Officer, Director
Offering amount
$54.2K
First sale
Mar 2024
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$149.8KofferedSep 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeremy FryzukDirector
  • Revati ShreeniwasExecutive Officer
  • Ian McDonaldExecutive Officer, Director
  • Douglas WilliamsonDirector
  • Jan Torleif PedersenExecutive Officer, Director
  • Ryan CheungExecutive Officer
  • Nils BottlerDirector
Offering amount
$149.8K
First sale
Sep 2022
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$220.3KofferedSep 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan KozikowskiDirector
  • Ian McDonaldExecutive Officer, Director
  • Jan Torleif PedersenExecutive Officer, Director
  • Nils BottlerDirector
  • Revati ShreeniwasExecutive Officer
  • Ryan CheungExecutive Officer
  • Jeremy FryzukDirector
Offering amount
$220.3K
First sale
Aug 2022
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$82.7KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan PedersenDirector
  • Gideon ShapiroExecutive Officer
  • Jeremy FryzukDirector
  • Ian McDonaldExecutive Officer, Director
  • Revati SheeniwasExecutive Officer
  • Alan KozikowskiExecutive Officer, Director
  • Nils BottlerDirector
  • Ryan CheungExecutive Officer
Offering amount
$82.7K
Amount sold
$82.7K
First sale
Feb 2022
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$59.8KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ian McDonaldExecutive Officer, Director
  • Nils BottlerDirector
  • Gideon ShapiroExecutive Officer
  • Revati SheeniwasExecutive Officer
  • Ryan CheungExecutive Officer
  • Alan KozikowskiExecutive Officer, Director
  • Jeremy FryzukDirector
  • Jan PedersenDirector
Offering amount
$59.8K
Amount sold
$59.8K
First sale
Feb 2022
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$623.6KofferedJun 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nils BottlerDirector
  • Revati SheeniwasExecutive Officer
  • Jeremy FryzukDirector
  • Alan KozikowskiExecutive Officer, Director
  • Gideon ShapiroExecutive Officer
  • Emer LeahyDirector
  • Ian McDonaldExecutive Officer, Director
  • Ryan CheungExecutive Officer
Offering amount
$623.6K
First sale
Jun 2021
Incorporated
Corporation, British Columbia, Canada, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does bright-minds do?
Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.
Who founded bright-minds?
bright-minds was founded by Alan Kozikowski, Ian McDonald in 2019.
Who are bright-minds's investors?
bright-minds's investors include PsyMed Ventures.
How much funding has bright-minds raised?
bright-minds has disclosed $36.6M raised across 9 of its 14 known rounds.
Where is bright-minds headquartered?
bright-minds is headquartered in New York, US.